Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management

Author(s): Cinzia Perrino, Gabriele G. Schiattarella, Fabio Magliulo, Federica Ilardi, Giuseppe Carotenuto, Giuseppe Gargiulo, Federica Serino, Marco Ferrone, Fernando Scudiero, Andreina Carbone, Bruno Trimarco, Giovanni Esposito

Journal Name: Current Vascular Pharmacology

Volume 12 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.

Keywords: Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [106 - 116]
Pages: 11
DOI: 10.2174/157016111201140327163302

Article Metrics

PDF: 48